Free Trial
NASDAQ:GYRE

Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Gyre Therapeutics logo
$8.21 +0.10 (+1.23%)
As of 12:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Gyre Therapeutics Stock (NASDAQ:GYRE)

Key Stats

Today's Range
$8.05
$8.26
50-Day Range
$6.65
$8.33
52-Week Range
$6.11
$19.00
Volume
31,388 shs
Average Volume
162,972 shs
Market Capitalization
$790.73 million
P/E Ratio
821.82
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Buy

Company Overview

Gyre Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
24th Percentile Overall Score

GYRE MarketRank™: 

Gyre Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 844th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Gyre Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Gyre Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Gyre Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gyre Therapeutics is 812.31, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.52.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gyre Therapeutics is 812.31, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.80.

  • Price to Book Value per Share Ratio

    Gyre Therapeutics has a P/B Ratio of 6.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Gyre Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.38% of the float of Gyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gyre Therapeutics has a short interest ratio ("days to cover") of 8.6.
  • Change versus previous month

    Short interest in Gyre Therapeutics has recently increased by 2.21%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Gyre Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Gyre Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.38% of the float of Gyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gyre Therapeutics has a short interest ratio ("days to cover") of 8.6.
  • Change versus previous month

    Short interest in Gyre Therapeutics has recently increased by 2.21%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Gyre Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Gyre Therapeutics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Gyre Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 10.00% of the stock of Gyre Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 23.99% of the stock of Gyre Therapeutics is held by institutions.

  • Read more about Gyre Therapeutics' insider trading history.
Receive GYRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GYRE Stock News Headlines

Gyre Therapeutics (NASDAQ:GYRE) Now Covered by HC Wainwright
When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.tc pixel
See More Headlines

GYRE Stock Analysis - Frequently Asked Questions

Gyre Therapeutics' stock was trading at $12.10 at the beginning of the year. Since then, GYRE shares have decreased by 33.3% and is now trading at $8.0750.

Gyre Therapeutics, Inc. (NASDAQ:GYRE) issued its earnings results on Monday, August, 11th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by $0.01. The company had revenue of $26.77 million for the quarter, compared to analyst estimates of $30.80 million. Gyre Therapeutics had a net margin of 4.08% and a trailing twelve-month return on equity of 7.67%.

Gyre Therapeutics' top institutional shareholders include Geode Capital Management LLC (0.43%), SBI Securities Co. Ltd. (0.25%), American Century Companies Inc. (0.01%) and MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. (0.01%). Insiders that own company stock include Songjiang Ma and Nassim Usman.
View institutional ownership trends
.

Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
8/11/2025
Today
8/28/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GYRE
Previous Symbol
NASDAQ:GYRE
CIK
1124105
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$18.00
Low Price Target
$18.00
Potential Upside/Downside
+119.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.01
Trailing P/E Ratio
821.82
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$12.09 million
Net Margins
4.08%
Pretax Margin
11.33%
Return on Equity
7.67%
Return on Assets
6.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.40
Quick Ratio
4.87

Sales & Book Value

Annual Sales
$102.19 million
Price / Sales
7.74
Cash Flow
$0.21 per share
Price / Cash Flow
39.29
Book Value
$1.34 per share
Price / Book
6.13

Miscellaneous

Outstanding Shares
96,313,000
Free Float
86,682,000
Market Cap
$790.73 million
Optionable
No Data
Beta
1.80
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:GYRE) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners